Highlights of This Issue

SPECIAL FEATURES

CCR Translations

4733 Prostate Cancer SubtyPINg BiomarkKers and Outcome: Is Clarity EmERGing?
Steven C. Smith and Scott A. Tomlins
See related article, p. 4904

4737 Twisting and Ironing: Doxorubicin Cardiotoxicity by Mitochondrial DNA Damage
Karin C. Nitiss and John L. Nitiss
See related article, p. 4873

Molecular Pathways

4740 Molecular Pathways: Targeting RAC–p21-Activated Serine–Threonine Kinase Signaling in RAS-Driven Cancers
Nicole M. Baker, Hoi Yee Chow, Jonathan Chernoff, and Channing J. Der

CANCER THERAPY: CLINICAL

4747 Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGF1 and IGFII, in Patients with Advanced Solid Tumors
Paul Haluska, Michael Meneeef, Elizabeth R. Plimack, Jonathan Rosenberg, Donald Northfelt, Theresa LaVallee, Li Shi, Xiang-Qing Yu, Patricia Burke, Jaiq Huang, Jaye Viner, Jennifer McDevitt, and Patricia LoRusso

4758 Is the "3+3" Dose-Escalation Phase I Clinical Trial Design Suitable for Therapeutic Cancer Vaccine Development? A Recommendation for Alternative Design
Osama E. Rahma, Emily Gammoh, Richard M. Simon, and Samir N. Khleif

4768 The Role of Age on Dose-Limiting Toxicities in Phase I Dose-Escalation Trials

4776 Phase I Study of RGB-286638, A Novel, Multitargeted Cyclin-Dependent Kinase Inhibitor in Patients with Solid Tumors
Diane A.J. van der Bissens, Herman Burger, Peter de Bruijn, Cor H.J. Lamers, Nicole Naus, Hannes Loefeler, Erik A.C. Wiemer, Ron H.J. Mathijsen, and Maja J.A. de Jonge

PERSONALIZED MEDICINE AND IMAGING

4784 A Three-microRNA Signature Predicts Responses to Platinum-Based Doublet Chemotherapy in Patients with Lung Adenocarcinoma
Motonobu Saito, Kouya Shiraiishi, Kenji Matsumoto, Aaron J. Schetter, Hiroko Ogata-Kawata, Naoto Tsuchiya, Hideo Kuninoh, Hiroshi Nokihara, Shun-ichi Watanabe, Koji Taura, Kensuke Kumamoto, Seiichi Takenoshita, Jun Yokota, Curtis C. Harris, and Takashi Kohn

4794 Clinical Significance of EpCAM mRNA-Positive Circulating Tumor Cells in Hepatocellular Carcinoma by an Optimized Negative Enrichment and qRT-PCR-Based Platform
Wei Guo, Xin-Rong Yang, Yun-Fan Sun, Min-Na Shen, Xiao-Lu Ma, Jing Wu, Chun-Yan Zhang, Yan Zhou, Yang Xu, Bo Hu, Xin Zhang, Jian Zhou, and Jia Fan

4806 Monitoring Reversal of MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer Using 3'-Deoxy-3'-[18F]-Fluorothymidine Positron Emission Tomography
Francesca Iommelli, Viviana De Rosa, Sara Gargiulo, Mariarosaria Panico, Marcello Monti, Adelaide Greco, Matteo Gramanzini, Giovanni Ortesecco, Rosa Fonti, Arturo Brunetti, and Silvana Del Vecchio

4816 Functional Ex Vivo Assay to Select Homologous Recombination–Deficient Breast Tumors for PARP Inhibitor Treatment
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>4827</td>
<td>Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses</td>
<td>Apostolia-Maria Tsimberidou, Sijin Wen, David S. Hong, Jennifer J. Wheeler, Gerald S. Falchook, Siqing Fu, Sarina Piha-Paul, Aung Naing, Filip Janku, Kenneth Aldape, Yang Ye, Razelle Kurzrock, and Donald Berry</td>
</tr>
<tr>
<td>4837</td>
<td>Systematically Defining Single-Gene Determinants of Response to Neoadjuvant Chemotherapy Reveals Specific Biomarkers</td>
<td>Agnieszka K. Witkiewicz, Uthra Balaji, and Erik S. Knudsen</td>
</tr>
<tr>
<td>4849</td>
<td>PI3K/mTOR Inhibition Markedly Potentiates HDAC Inhibitor Activity in NHL Cells through BIM- and MCL-1–Dependent Mechanisms In Vitro and In Vivo</td>
<td>Mohamed Rahmani, Mandy Mayo Aust, Elisa C. Benson, LaShanale Wallace, Jonathan Friedberg, and Steven Grant</td>
</tr>
<tr>
<td>4861</td>
<td>On-Target Effect of FK866, a Nicotinamide Phosphoribosyl Transferase Inhibitor, by Apoptosis-Mediated Death in Chronic Lymphocytic Leukemia Cells</td>
<td>Iris Gehrke, Eric D.J. Bouchard, Sara Beiggi, Armando G. Poeppl, James B. Johnston, Spencer B. Gibson, and Versha Banerji</td>
</tr>
<tr>
<td>4873</td>
<td>Mitochondrial Topoisomerase I (Top1mt) Is a Novel Limiting Factor of Doxorubicin Cardiotoxicity</td>
<td>Salim Khiati, Ilaria Dalla Rosa, Carole Sourbier, Xuefei Ma, V. Ashutosh Rao, Leonard M. Neckers, Hongliang Zhang, and Yves Pommier</td>
</tr>
<tr>
<td>4882</td>
<td>Demethylating Drugs as Novel Analgesics for Cancer Pain</td>
<td>Chi T. Viet, Dongmin Dang, Yi Ye, Kentaro Ono, Ronald R. Campbell, and Brian L. Schmidt</td>
</tr>
<tr>
<td>4904</td>
<td>SPINK1 Protein Expression and Prostate Cancer Progression</td>
<td>Richard Flavin, Andreas Pettersson, Whitney K. Hendrickson, Michelangelo Fiorentino, Stephen Finn, Lauren Kunz, Gregory L. Judson, Rosina Lis, Dyane Bailey, Christopher Fiore, Elizabeth Nuttall, Neil E. Martin, Edward Stack, Kathryn L. Penney, Jennifer R. Rider, Jennifer Sinnott, Christopher Sweeney, Howard D. Sesso, Katja Fall, Edward Giovannucci, Philip Kantoff, Meir Stampfer, Massimo Loda, and Lorelei A. Mucci</td>
</tr>
<tr>
<td>4949</td>
<td>T-box Transcription Factor Brachyury Is Associated with Prostate Cancer Progression and Aggressiveness</td>
<td>Filipe Pinto, Nelma Perteiga-Gomes, Márcia S. Pereira, José R. Vitçaino, Pedro Monteiro, Rui M. Henriques, Fátima Baltazar, Raquel P. Andrade, and Rui M. Reis</td>
</tr>
</tbody>
</table>
Excess of Proximal Microsatellite-Stable Colorectal Cancer in African Americans from a Multiethnic Study

LETTERS TO THE EDITOR

Androstenedione Is the Preferred Androgen Source in Hormone Refractory Prostate Cancer—Letter
Nima Sharifi and Richard J. Auchus

CORRECTION

Correction: Prevalence and Clinical Implications of Epstein–Barr Virus Infection in De Novo Diffuse Large B-Cell Lymphoma in Western Countries

ABOUT THE COVER

The cover shows results from FISH analysis of prostate cancer cells with ERG rearrangement (top; loss of one green signal indicating translocation through deletion) and hemizygous PTEN deletion (bottom; loss of one red signal with preservation of green centromeric signals). For details, see the article by Khani and colleagues on page 4925 of this issue.
Clinical Cancer Research

20 (18)


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/20/18

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.